BioCryst Pharma (BCRX) Stock Price, Quote, News & History | Benzinga

BioCryst Pharmaceuticals Inc (BCRX) Stock Price, Quote, News & History

BCRXNASDAQ

Trade with Public

Trade with Public

$10.36

0.525.28%

Last update: Aug 11, 3:34 PM

Earnings: Q2 2026 Earnings were released on Wed Aug 5th, before the market open

Conference Call: The most recent conference call started at 8:30 AM, 6 days ago

Click to view the webcast

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$9.86

Close

-

Volume / Avg.

3.64M / 4.84M

Day Range

$9.78 - $10.59

52 Wk Range

6.00 - 11.22

Market Cap

$2.65B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

64

Short Interest

12.3%

Days to Cover

5.95

Recent BioCryst Pharmaceuticals, Inc. News

Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Canaccord cut Strategy's target, Barclays upgraded Watts Water, Rosenblatt boosted Comcast, Goldman increased State Street, Evercore raised Owens Corning, Cantor Fitzgerald boosted BioCryst Pharma, BTIG raised Edwards Lifesciences.

Avi Kapoor

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, reaffirmed FY2026 sales guidance, and received positive price target changes from analysts.

Avi Kapoor

Why Paranovus Entertainment Technology Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket

PAVS stock rose 65.6% in pre-market trading after ending sales agreement with A.G.P/Alliance Global Partners and other stocks moved.

Avi Kapoor

BioCryst Gets FDA Approval To Treat Rare Childhood Swelling Disorder With Oral Drug

BioCryst secures FDA approval for Orladeyo oral pellets, expanding preventive HAE therapy to children ages 2 to under 12.

Vandana Singh

Top Stocks With Earnings This Week: Joby, IonQ, AMD and More

Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.

Erica Kollmann

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

376.14M

Investing Cash Flow (TTM)

-448.71M

Financing Cash Flow (TTM)

124.63M

Free Cash Flow (TTM)

373.38M

Capital Expenditure (TTM)

-2.76M

Net Change in Cash (TTM)

52.05M

Analyst Trends and Forecast

2

May

2

Jun

1

1

Jul

2

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.95B

PE Ratio (TTM)

-

PE Ratio (FWD)

28.90

PEG Ratio (TTM)

-

PS Ratio (TTM)

2.45

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-14.23%

Earnings Yield % (FWD)

3.46%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

6.17

Book Value / Share

-$1.78

Company Debt

Total Debt

$778.38M

LT Debt

$778.38M

LT Debt Issuance (TTM)

$400.00M

LT Debt Repayment (TTM)

-$232.14M

Total Cash

$154.97M

Debt to Equity

-

Issuance of Debt (TTM)

$167.87M

Repayment of Debt (TTM)

-$232.14M

Key Statistics

Open

$9.86

Close

-

Volume / Avg.

3.64M / 4.84M

Day Range

$9.78 - $10.59

52 Wk Range

6.00 - 11.22

Market Cap

$2.65B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

64

Short Interest

12.3%

Days to Cover

5.95

About

Sector

Health Care

Industry

Biotechnology

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple sci...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy BioCryst Pharma (BCRX) stock?

A

You can purchase shares of BioCryst Pharma (NASDAQ:BCRX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are BioCryst Pharma (BCRX) competitors?

A

Other companies in BioCryst Pharma’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for BioCryst Pharma (BCRX) stock?

A

BioCryst Pharma has a consensus price target of $20.79.

Q

What is the current price for BioCryst Pharma (BCRX)?

A

The stock price for BioCryst Pharma (NASDAQ: BCRX) is $10.36 last updated August 11, 2026 at 3:34 PM EDT.

Q

Does BioCryst Pharma (BCRX) pay a dividend?

A

There are no upcoming dividends for BioCryst Pharma.

Q

When is BioCryst Pharma (NASDAQ:BCRX) reporting earnings?

A

BioCryst Pharma does not have any upcoming earnings scheduled.

Q

Is BioCryst Pharma (BCRX) going to split?

A

There is no upcoming split for BioCryst Pharma.

Q

What sector and industry does BioCryst Pharma (BCRX) operate in?

A

BioCryst Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.